Evaluating Clover Health Investments (CLOV) Valuation After A Sharp Short‑Term Share Price Rebound

What recent performance says about Clover Health Investments (CLOV)

Clover Health Investments (CLOV) has attracted fresh attention after a sharp share price move, with the stock showing a 5.2% gain over the past day and a 48.4% gain over the past month.

See our latest analysis for Clover Health Investments.

The recent 48.4% 1-month share price return sits against a 17.0% share price return year to date and a 24.8% decline in the 1-year total shareholder return. This points to momentum rebuilding after a weaker longer-term experience.

If you are looking beyond Clover Health Investments, this could be a useful moment to scan for other healthcare and AI opportunities using our screener for 35 healthcare AI stocks.

With Clover Health trading near its analyst price target and sitting on a very large estimated intrinsic discount, investors now have to ask whether this stock is still undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 10% Overvalued

Clover Health's most followed narrative pegs fair value at $2.82, almost exactly where the last close of $2.82 sits, which raises clear questions about how much upside is left from here.

The analysts have a consensus price target of $2.82 for Clover Health Investments based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.2, and the most bearish reporting a price target of just $2.5.

Read the complete narrative.

Want to see what sits underneath that tight price range? The whole narrative leans on faster revenue gains, improving margins and a punchy future earnings multiple, all working together to justify the fair value.

Result: Fair Value of $2.82 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, those assumptions can be knocked off course if medical costs stay elevated, or if Medicare Advantage reimbursement and rating rules shift against current expectations.

Find out about the key risks to this Clover Health Investments narrative.

Another Way To Look At Value

The analyst narrative leans on earnings forecasts and a high future P/E, but the current revenue multiple tells a different story. Clover Health trades on a P/S of 0.7x versus 1.2x for the wider US Healthcare sector and 1.9x for peers, while the fair ratio sits at 0.8x.

That gap suggests the market is pricing in more risk than the fair ratio implies, even though the discount is smaller against it than against peers. The key question for you is whether current execution and balance sheet strength justify that gap or whether the ratio could move closer to the fair ratio over time.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on value and sentiment so far? Take a closer look at the numbers, weigh the trade off between concerns and potential upside, and check the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Clover Health has sharpened your focus, do not stop here. The next step is lining up fresh ideas that match how you actually like to invest.

• Target potential turnaround stories by scanning 25 elite penny stocks with strong financials that pair low share prices with stronger financial profiles than many expect.
• Zero in on quality at a discount by using the 51 high quality undervalued stocks to spot companies where fundamentals and price look out of sync.
• Prioritise resilience by filtering for companies in the solid balance sheet and fundamentals stocks screener (44 results) that emphasise financial strength and healthier looking balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com